Glenmark Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company is almost debt free
- Latest quarter profit grew 122.8% YoY, showing strong momentum
- Company generates healthy free cash flow
- Company has a consistent dividend-paying track record
CONS
- Company is loss-making at the operating / net level
- Recent results are weak - TTM profit is down 74.8% versus prior year
- Receivables are growing faster than sales - a possible quality concern
- Interest coverage is weak at -2.4x - earnings barely cover interest
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.10x)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BIOCON | 390.95 | 128.63 | 63712.89 | 0.13 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,098 | 2,170 | 1,304 | 2,077 | 2,297 | 2,595 | 2,209 | 1,910 | 2,179 | 1,220 | 2,328 | 2,208 | 2,435 | |
| 1,659 | 1,790 | 1,549 | 1,651 | 1,698 | 1,857 | 1,757 | 1,669 | 1,667 | 1,717 | 1,864 | 2,115 | 1,907 | |
| Operating Profit | 439 | 380 | -245 | 426 | 598 | 737 | 451 | 241 | 512 | -497 | 464 | 93 | 528 |
| OPM % | 20.91% | 17.53% | -18.80% | 20.53% | 26.05% | 28.42% | 20.44% | 12.62% | 23.50% | -40.76% | 19.93% | 4.19% | 21.67% |
| 18 | 54 | 234 | 5,933 | 56 | 83 | 129 | -91 | -254 | -646 | -68 | -61 | -108 | |
| Interest | 62 | 58 | 74 | 83 | 15 | 12 | 8 | 13 | 15 | 23 | 22 | 18 | 23 |
| Depreciation | 49 | 50 | 51 | 52 | 53 | 55 | 55 | 56 | 58 | 59 | 59 | 60 | 62 |
| Profit before Tax | 392 | 389 | -76 | 6,295 | 618 | 795 | 559 | 181 | 401 | -906 | 347 | -107 | 866 |
| Tax % | 30.71% | 22.35% | 72.97% | 26.71% | 26.62% | 25.16% | 26.04% | 18.44% | 17.68% | 18.45% | 18.60% | 31.19% | 15.06% |
| Net Profit | 272 | 302 | -20 | 4,614 | 454 | 595 | 414 | 148 | 330 | -739 | 282 | -74 | 736 |
| 9.63 | 10.72 | -0.72 | 163.50 | 16.08 | 21.09 | 14.66 | 5.24 | 11.70 | -26.19 | 10.00 | -2.62 | 26.07 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,096 | 6,432 | 6,305 | 6,713 | 7,568 | 8,142 | 8,221 | 7,891 | 9,226 | 8,440 | 8,190 | |
| 5,197 | 5,107 | 4,977 | 5,408 | 5,678 | 6,453 | 6,748 | 6,649 | 6,982 | 7,363 | 7,603 | |
| Operating Profit | 2,899 | 1,326 | 1,327 | 1,304 | 1,890 | 1,688 | 1,473 | 1,242 | 2,244 | 1,077 | 587 |
| OPM % | 35.81% | 20.61% | 21.05% | 19.43% | 24.98% | 20.74% | 17.92% | 15.73% | 24.32% | 12.77% | 7.17% |
| -88 | 180 | 821 | 625 | 470 | 1,045 | 490 | 6,238 | 177 | -1,029 | -883 | |
| Interest | 153 | 191 | 224 | 256 | 266 | 236 | 207 | 277 | 49 | 79 | 87 |
| Depreciation | 105 | 96 | 106 | 139 | 151 | 160 | 184 | 202 | 219 | 236 | 241 |
| Profit before Tax | 2,553 | 1,219 | 1,818 | 1,535 | 1,944 | 2,337 | 1,572 | 7,001 | 2,154 | -266 | 199 |
| Tax % | 16.15% | 16.78% | 18.14% | 11.74% | 15.14% | 14.53% | 23.10% | 26.19% | 25.24% | 24.53% | -2.89% |
| Net Profit | 2,141 | 1,014 | 1,488 | 1,355 | 1,649 | 1,998 | 1,209 | 5,167 | 1,610 | -201 | 205 |
| EPS | 75.84 | 35.95 | 57.49 | 48.00 | 58.46 | 70.80 | 42.84 | 183.11 | 57.07 | -7.12 | — |
| Dividend Payout % | 2.64% | 5.56% | 3.79% | 5.21% | 4.28% | 3.53% | 5.84% | 1.37% | 4.38% | -35.13% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 3%
- 5 Years:
- 2%
- 3 Years:
- 1%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- 11%
- 5 Years:
- 36%
- 3 Years:
- 44%
- 1 Year:
- 14%
RETURN ON EQUITY
- 10 Years:
- 12%
- 5 Years:
- 10%
- 3 Years:
- 10%
- Last Year:
- -1%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| 9,407 | 10,353 | 11,903 | 13,184 | 14,766 | 16,708 | 17,847 | 22,940 | 24,473 | 24,117 | |
| 2,779 | 2,984 | 3,223 | 3,779 | 3,818 | 3,105 | 3,417 | 654 | 924 | 1,489 | |
| Trade Payables | 1,467 | 1,555 | 1,668 | 1,585 | 1,623 | 1,939 | 2,093 | 2,700 | 2,182 | 2,746 |
| 1,643 | -315 | -392 | 1,161 | 2,773 | 3,840 | 3,540 | 5,087 | 5,163 | 5,836 | |
| Total Liabilities | 15,324 | 14,604 | 16,431 | 19,738 | 23,007 | 25,619 | 26,925 | 31,410 | 32,770 | 34,216 |
| 1,596 | 1,699 | 1,413 | 1,612 | 1,722 | 1,752 | 1,746 | 1,756 | 1,979 | 2,028 | |
| Capital Work in Progress | 235 | 354 | 209 | 152 | 93 | 101 | 159 | 175 | 121 | 67 |
| 1,867 | 3,213 | 3,269 | 4,714 | 6,990 | 8,559 | 10,333 | 12,965 | 15,195 | 15,202 | |
| 1,145 | 1,111 | 911 | 838 | 762 | 952 | 1,090 | 1,143 | 1,369 | 1,288 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,484 | 2,550 | 3,306 | |
| Cash & Bank | 252 | 177 | 256 | 88 | 16 | 30 | 94 | 129 | 133 | 293 |
| 10,229 | 8,050 | 10,371 | 12,334 | 13,423 | 14,225 | 13,503 | 12,757 | 11,423 | 12,032 | |
| Total Assets | 15,324 | 14,604 | 16,431 | 19,738 | 23,007 | 25,619 | 26,925 | 31,410 | 32,770 | 34,216 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,524 | 1,416 | 2,888 | 1,918 | 1,579 | 1,607 | 1,890 | -495 | 589 | 543 | |
| Cash from Investing | -2,580 | -1,137 | -2,256 | -1,607 | -1,235 | -897 | -431 | 3,197 | -490 | 569 |
| Cash from Financing | 1,879 | -62 | -155 | -139 | -81 | -305 | -978 | -2,666 | -95 | -952 |
| 177 | -75 | 79 | -168 | -73 | 14 | 64 | 35 | 4 | 160 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.
2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ".
2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating
2026-08-21 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package".
2026-08-20 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray".
2026-08-15 - Glenmark Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-13 - Letter to shareholders whose email address are not registered providing the Web Link of Integrated Annual Report
2026-08-13 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026
2026-08-11 - Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
News
Recent coverage and analyst commentary for GLENMARK
Loading news…
AI Stock Analyst
Glenmark Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account